Skip to content

Insider · CIK 0001954991

Paul Herzich

officer

Files at SLDB (Solid Biosciences Inc.). First filing Dec 4, 2024, latest Feb 18, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $26k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

SLDB: Solid Biosciences Inc.

SLDBOct 9, 2026 · close 6.87

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
0Weak
SLDBsell 610b5-1
Solid Biosciences Inc.
$11k
2,688 shares
-13%-
20Weak
SLDBsell 4
Solid Biosciences Inc.
$16k
2,777 shares
-19%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Feb 13, 2025SLDB
Solid Biosciences Inc.
MOption exercise
Common Stock10b5-1
+7,187--21,076Feb 18, 2025
Feb 14, 2025SLDB
Solid Biosciences Inc.
SOpen-market sale
Common Stock10b5-1
-2,688$3.96$11k18,388Feb 18, 2025
Feb 13, 2025SLDB
Solid Biosciences Inc.
MOption exercise
Restricted Stock Unitsderivative10b5-1
-7,187$0.00$021,563Feb 18, 2025
Jan 31, 2025SLDB
Solid Biosciences Inc.
AGrant or award
Restricted Stock Unitsderivative
+98,700$0.00$098,700Feb 11, 2025
Dec 2, 2024SLDB
Solid Biosciences Inc.
MOption exercise
Common Stock
+7,239--14,959Dec 4, 2024
Dec 3, 2024SLDB
Solid Biosciences Inc.
SOpen-market sale
Common Stock
-2,777$5.60$16k12,182Dec 4, 2024
Dec 2, 2024SLDB
Solid Biosciences Inc.
MOption exercise
Restricted Stock Unitsderivative
-7,239$0.00$014,478Dec 4, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Paul Herzich: insider trades and track record | InsiderTell